RELAPSING MULTIPLE SCLEROSIS

This early-stage study is testing a single dose of an experimental cell therapy called YTB323 in about 28 adults with relapsing multiple sclerosis. The goal is to see if this treatment is safe and can help control the disease in patients whose current high-efficacy medications ar…

This study is testing whether a stem cell transplant can better control multiple sclerosis (MS) than the best available drugs in people whose MS stays active despite treatment. It will involve 156 adults whose MS has flared up despite taking strong medications. Participants will …

This study is testing how well the drug ocrelizumab works to control multiple sclerosis (MS) in Chinese patients. It will include 60 people with either relapsing or primary progressive forms of MS. The main goals are to see if the drug reduces disease activity and to measure its …

This study is for people with relapsing multiple sclerosis (MS) who are currently getting ocrelizumab infusions. It will test if switching to a new pill called remibrutinib works as well to control the disease. About 360 participants, aged 40-70, will be randomly assigned to eith…

This study is testing an oral medication called fenebrutinib in children and adolescents (ages 10 to under 18) who have relapsing multiple sclerosis (RMS). The main goals are to see how the drug behaves in young bodies, measure its effect on new brain lesions seen on MRI scans, a…

This study is testing a modified dosing schedule for the multiple sclerosis drug ublituximab. It aims to see if the new schedule is effective at reducing brain lesions and is safe for people with relapsing MS. The trial will also look at how the drug works in people who did not h…

This study is testing if a new drug called CYB704 works the same way as the established MS treatment Ocrevus. Researchers will compare how the two drugs are processed by the body, their effectiveness, and their side effects in 175 adults with relapsing multiple sclerosis. The goa…

This study aims to understand the real-world safety and effectiveness of the multiple sclerosis drug BRIUMVI. It will follow 500 people with MS who are starting this treatment in their regular care settings. The main goal is to see how well the drug controls relapses and to monit…

This study is testing if it's safe and effective for people with stable relapsing multiple sclerosis (MS) to switch from powerful infusion/injection therapies (anti-CD20 drugs) to a daily pill called ozanimod. The goal is to see if the milder pill can maintain disease control whi…

This study is testing if giving the MS medication ublituximab as a simple injection under the skin (subcutaneous) works as well as the current method of receiving it through an IV drip. It will involve 360 people with relapsing multiple sclerosis to see if the new method controls…

This study aims to measure how much of the multiple sclerosis medication BRIUMVI passes into breast milk when breastfeeding mothers take it. Researchers will collect milk samples from 16 participants over 24 hours after their dose to track the drug's levels. The goal is to gather…

This study aims to understand how well people with relapsing multiple sclerosis (MS) in Germany stay on their prescribed injectable or oral treatments in real-world settings. It will follow about 800 patients for up to four years, collecting data through questionnaires and medica…